FDA’s De Novo approval of BrainSee represents a major advancement in Alzheimer’s diagnostics. Utilizing cutting-edge image processing and medical AI, BrainSee establishes a new standard for predicting progression from amnestic mild cognitive impairment (aMCI) to Alzheimer’s dementia. This breakthrough is a significant step in proactive brain health management, offering a fully non-invasive, convenient, and globally accessible screening solution, to be prioritized before other tests or treatments.
SAN FRANCISCO, Jan. 12, 2024 /PRNewswire-HISPANIC PR WIRE/ — Today marks a turning point in the battle against Alzheimer’s disease as Darmiyan, Inc., a leading company in brain health innovation announces the FDA’s approval of its first-in-class (De Novo) clinical test, BrainSee. This approval marks a pivotal advancement in brain health and opens the door to untapped market potential in brain disease diagnosis and management.
BrainSee is the first clinical application of Darmiyan’s patented core proprietary technology that is based on 40+ years of cutting-edge brain science, powered by advanced whole-brain image analysis and medical AI. It is a highly-scalable and fully-automated software platform that combines standard clinical brain MRI and cognitive assessments – part of the routine, non-invasive workup of patients concerned with memory loss – and generates an objective score that predicts the likelihood of progression from aMCI to Alzheimer’s dementia within 5 years. BrainSee addresses a critical unmet need for over 10 million Americans and over 100 million patients worldwide grappling with aMCI. With an aging global population, the socio-economic impact of BrainSee is expected to grow rapidly and exponentially.
“Our vision is to redefine brain health screening and monitoring standards and impact the lives of patients and their family members in a meaningful way. BrainSee is the first product of this vision, backed by our solid technological infrastructure that is capable of driving further transformations and scalable innovations in the brain health landscape,” stated Dr. Padideh Kamali-Zare, Founder and CEO of Darmiyan.
Early screening and risk stratification by BrainSee enables timely and personalized treatments for those aMCI patients at high risk of progression to Alzheimer’s dementia, aiming to delay dementia onset, while reassuring those at lower risk of progression, hence reducing the need for costly and invasive tests and the heavy burdens of financial and emotional abuse. This shifts the patient experience from prolonged anxiety to proactive management, which is crucial in an era of emerging Alzheimer’s treatments where accurate prognosis can help determine suitable treatment candidates. The economic impact of BrainSee will be significant for all stakeholders in healthcare, promising to reduce the billions of dollars annually spent on Alzheimer’s care, through more effective management and treatment.
BrainSee was previously granted FDA breakthrough designation in 2021. It stands out for its prognostic accuracy, patient convenience, same-day test results and seamless integration into the clinical workflow. Global availability of MRI significantly enhances BrainSee’s clinical utility. Most notably, BrainSee shifts the paradigm in aMCI workup from biomarker-based methods that have limited real-world capabilities due to their invasiveness, non-specificity, cost, and inaccessibility, to non-invasive and actionable forecasts of future improvement or progression.
BrainSee’s FDA approval coincided with the JP Morgan HealthCare conference in San Francisco. The platform is now available to physicians via a secure and HIPAA-compliant web portal. For more information visit brainsee.ai.
About Darmiyan:
Darmiyan is a pioneering brain technology (deep-tech) company in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company’s mission is to enhance brain health, equipping physicians with tools for precise and personalized patient care, thereby optimizing health outcomes.
Logo – https://mma.prnewswire.com/media/1153911/Darmiyan.jpg
SOURCE Darmiyan
